Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD886
- Development stage
- Unknown
- Lead developer
- Pelthos Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
CD886 is a small molecule nitric oxide donor being developed by Pelthos Therapeutics (formerly LNHC) and its subsidiary, Channel Therapeutics, for the treatment of neuropathic pain. The drug utilizes the proprietary NITRICIL™ technology platform, which involves nitric oxide-based chemistry to modulate pain signaling. CD886 is currently in Phase 3 clinical development for Idiopathic Peripheral Neuropathy (IPN) and Erythromelalgia (EM). It has been granted Fast Track designation by the FDA for the treatment of Erythromelalgia. The therapeutic approach focuses on the controlled release of nitric oxide to address the underlying pathophysiology of peripheral nerve pain, although specific downstream molecular targets have not been publicly disclosed.
Beyond the preview
Go deeper on CD886.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD886.